Regentis Biomaterials (RGNT) Form 6-K highlights long-term GelrinC cartilage repair durability

Rhea-AI Filing Summary

Regentis Biomaterials Ltd. submitted a Form 6-K as a foreign private issuer, providing investors with access to a new company press release. The filing furnishes a press release titled “Regentis’ GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation,” which discusses long-term durability results for its GelrinC cartilage repair product using quantitative MOCART imaging assessment. The press release is attached as Exhibit 99.1 and incorporated by reference.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of January 2026

Commission file number: 001-42834

REGENTIS BIOMATERIALS LTD.

(Translation of registrant’s name into English)

60 Medinat Hayehudim Street, 4676652, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the registrant’s press release issued on January 6, 2026, titled “Regentis’ GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation.”

A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Regentis’ GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Regentis Biomaterials Ltd.
Date: January 6, 2026	By:	/s/ Ehud Geller
	Name:	Ehud Geller
	Title:	Chairman and Chief Executive Officer

3

FAQ

What does Regentis Biomaterials (RGNT) disclose in this Form 6-K?

Regentis Biomaterials uses this Form 6-K to furnish a press release about its GelrinC product. The release focuses on long-term durability of cartilage repair evaluated using quantitative MOCART imaging and is attached as Exhibit 99.1.

What is the subject of Regentis Biomaterials’ attached press release?

The attached press release is titled “Regentis’ GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation.” It highlights durability findings for GelrinC in cartilage repair assessed through quantitative MOCART analysis.

Which exhibit is included with Regentis Biomaterials’ January 2026 Form 6-K?

The Form 6-K includes Exhibit 99.1, a press release titled “Regentis’ GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation.” This exhibit is expressly incorporated by reference into the report.

Who signed the Regentis Biomaterials (RGNT) Form 6-K filing?

The Form 6-K was signed on behalf of Regentis Biomaterials Ltd. by Ehud Geller. He is identified in the document as the company’s Chairman and Chief Executive Officer, acting as the duly authorized signatory.

What is GelrinC as referenced in Regentis Biomaterials’ Form 6-K?

GelrinC, referenced in the furnished press release, is a Regentis Biomaterials product for cartilage repair. The press release states that GelrinC’s long-term durability in cartilage repair was evaluated through quantitative MOCART imaging analysis.